You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Dow
Johnson and Johnson
Colorcon
AstraZeneca

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for BIAL - PORTELA & CA S.A. v. Dr. Reddy's Laboratories, Ltd. (D. Del. 2018)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

BIAL - PORTELA & CA S.A. v. Dr. Reddy's Laboratories, Ltd. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-03-02
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Colm F. Connolly
Jury Demand None Referred To
Parties BIAL - HOLDING, S.A.; BIAL - PORTELA & CA S.A.; DR. REDDY'S LABORATORIES, INC.; DR. REDDY'S LABORATORIES, LTD.; SUNOVION PHARMACEUTICALS INC.
Patents 8,372,431; 9,206,135; 9,566,244; 9,643,929; 9,750,747; 9,763,954
Attorneys Andrew Colin Mayo; Charles T. Collins-Chase; Danielle C. Pfifferling; Eve H. Ormerod; H. Howard Wang; Jack B. Blumenfeld; James B. Monroe; James P. Barabas; Jennifer H. Roscetti; Karen Jacobs; Lauren J. Dowty; Meredith H. Boerschlein; Neal C. Belgam; Steven J. Balick; Stuart D. Sender
Firms Morris, Nichols, Arsht & Tunnell; Smith, Katzenstein, & Jenkins LLP
Link to Docket External link to docket
Small Molecule Drugs cited in BIAL - PORTELA & CA S.A. v. Dr. Reddy's Laboratories, Ltd.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for BIAL - PORTELA & CA S.A. v. Dr. Reddy's Laboratories, Ltd. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,372,431; 9,206,135; 9,566,244… 2 March 2018 1:18-cv-00341 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 9 civil action for patent infringement of U.S. Patent Nos. 8,372,431 (“the ‘431 patent”), 9,206,135 (“the…“the ‘135 patent”), 9,566,244 (“the ‘244 patent”), 9,643,929 (“the ‘929 patent”), 9,750,747 (“the ‘747…‘747 patent”) and 9,763,954 (“the ‘954 patent”) (collectively, “patents-in-suit”) arising under the …civil action for patent infringement and declaratory judgement arising under the patent laws of the United… The Patents-in-Suit 35. DRL admits that the ‘431 patent, on its face, is entitled External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Mallinckrodt
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.